Incyte (INCY) Stock Forecast & Price Target

Compare

1,771 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

INCY Analyst Ratings

Moderate Buy

8 Buy

10 Hold

1 Sell

Based on 19 analysts giving stock ratings to

Incyte

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

INCY Stock 12 Month Forecast

Average Price Target

$85.71

▼(-1.67% Downside)

Based on 19 Wall Street analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is $85.71 with a high forecast of $115.00 and a low forecast of $60.00. The average price target represents a -1.67% change from the last price of $87.17.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"59":"$59","116":"$116","73.25":"$73.3","87.5":"$87.5","101.75":"$101.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$115.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":85.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$85.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$60.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[59,73.25,87.5,101.75,116],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.98,88.21230769230769,90.44461538461539,92.67692307692307,94.90923076923077,97.14153846153846,99.37384615384616,101.60615384615384,103.83846153846154,106.07076923076923,108.30307692307693,110.53538461538461,112.7676923076923,{"y":115,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.98,85.95923076923077,85.93846153846154,85.9176923076923,85.89692307692307,85.87615384615384,85.85538461538461,85.83461538461539,85.81384615384616,85.79307692307692,85.77230769230769,85.75153846153846,85.73076923076923,{"y":85.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.98,83.98153846153846,81.98307692307692,79.98461538461538,77.98615384615385,75.98769230769231,73.98923076923077,71.99076923076923,69.99230769230769,67.99384615384616,65.99538461538461,63.99692307692308,61.99846153846154,{"y":60,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":65.66,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.13,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.24,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.16,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.31,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$115.00

Average Price Target$85.71

Lowest Price Target$60.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jay Olson

Oppenheimer

$82

Hold

-5.93%

Downside

Downgraded

10/08/25

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS) and Incyte (NASDAQ: INCY)INCY outperformed YTD (+26% vs. NBI +18% and S&P 500 +14%) based on high expectations for Opzelura, povorcitinib, mCALR, CDK2i, and new management. We downgrade to Perform from Outperform based on our belief that this solid stretch for INCY shares has run its course and reached fair valuation. Our $82 PT is based on our estimates of a relatively stable top-line declining to $4.25B in 2030E from $4.89B in 2025E slightly above consensus revenue estimates of $3.95B (2030E) and $4.83B (2025E), respectively. We believe consensus revenue estimates already reflect Opzelura upside and povorcitinib (post-sonelokimab update). With INCY shares up +28% (S&P 500 +12%) since the mCALR update at EHA, we suspect there's already a reasonable valuation built in for both ET and MF, suggesting that expectations are high for the ASH update.

Marc Frahm

TD Cowen

$89

Buy

2.10%

Upside

Reiterated

09/26/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Brian Abrahams

RBC Capital

$72→$81

Hold

-7.08%

Downside

Reiterated

09/24/25

Incyte (INCY) Gets a Hold from RBC Capital

Stephen Willey

Stifel Nicolaus

$110→$115

Buy

31.93%

Upside

Reiterated

09/22/25

Incyte price target raised to $115 from $110 at StifelIncyte price target raised to $115 from $110 at Stifel

Michael Schmidt

Guggenheim

$86

Hold

-1.34%

Downside

Reiterated

09/18/25

Guggenheim Keeps Their Hold Rating on Incyte (INCY)

Tazeen Ahmad

Bank of America Securities

$104

Buy

19.31%

Upside

Reiterated

09/18/25

Incyte's Growth Potential Boosted by Opzelura Approval and Strategic Focus on Myeloproliferative Neoplasms

Peter Lawson

Barclays

$90

Buy

3.25%

Upside

Reiterated

09/18/25

Barclays Keeps Their Buy Rating on Incyte (INCY)

Reni Benjamin

Citizens JMP

―

Hold

―

Reiterated

09/18/25

Citizens JMP Keeps Their Hold Rating on Incyte (INCY)

Judah Frommer

Morgan Stanley

$79

Hold

-9.37%

Downside

Reiterated

09/17/25

Incyte's Povorcitinib Shows Promise but Faces Competitive Challenges: Hold Rating Maintained

Jessica Fye

J.P. Morgan

$67→$73

Hold

-16.26%

Downside

Reiterated

08/22/25

Incyte price target raised to $73 from $67 at JPMorganIncyte price target raised to $73 from $67 at JPMorgan

Derek Archila

Wells Fargo

$67→$89

Buy

2.10%

Upside

Upgraded

08/06/25

Analysts Conflicted on These Healthcare Names: Incyte (NASDAQ: INCY) and Y-Mabs Therapeutics (NASDAQ: YMAB)

Evan Seigerman

BMO Capital

$60

Sell

-31.17%

Downside

Reiterated

08/04/25

Incyte (INCY) Receives a Sell from BMO Capital

Mara Goldstein

Mizuho Securities

$70→$74

Hold

-15.11%

Downside

Reiterated

08/04/25

Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and Incyte (NASDAQ: INCY)INCY (N, increasing PT to $74 from $70): We are raising our PT to $74 (from $70), broadly in‐line with the 2Q25 earnings revenue guidance raise for FY2025.

David Lebowitz

Citi

$88→$103

Buy

18.16%

Upside

Reiterated

07/30/25

Incyte price target raised to $103 from $88 at CitiIncyte price target raised to $103 from $88 at Citi

Andrew Berens

Leerink Partners

$96→$103

Buy

18.16%

Upside

Reiterated

07/30/25

Incyte's Strong Financial Performance and Strategic Initiatives Under New Leadership Drive Buy Rating

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jay Olson

Oppenheimer

$82

Hold

-5.93%

Downside

Downgraded

10/08/25

Marc Frahm

TD Cowen

$89

Buy

2.10%

Upside

Reiterated

09/26/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Brian Abrahams

RBC Capital

$72→$81

Hold

-7.08%

Downside

Reiterated

09/24/25

Incyte (INCY) Gets a Hold from RBC Capital

Stephen Willey

Stifel Nicolaus

$110→$115

Buy

31.93%

Upside

Reiterated

09/22/25

Incyte price target raised to $115 from $110 at StifelIncyte price target raised to $115 from $110 at Stifel

Michael Schmidt

Guggenheim

$86

Hold

-1.34%

Downside

Reiterated

09/18/25

Guggenheim Keeps Their Hold Rating on Incyte (INCY)

Tazeen Ahmad

Bank of America Securities

$104

Buy

19.31%

Upside

Reiterated

09/18/25

Incyte's Growth Potential Boosted by Opzelura Approval and Strategic Focus on Myeloproliferative Neoplasms

Peter Lawson

Barclays

$90

Buy

3.25%

Upside

Reiterated

09/18/25

Barclays Keeps Their Buy Rating on Incyte (INCY)

Reni Benjamin

Citizens JMP

―

Hold

―

Reiterated

09/18/25

Citizens JMP Keeps Their Hold Rating on Incyte (INCY)

Judah Frommer

Morgan Stanley

$79

Hold

-9.37%

Downside

Reiterated

09/17/25

Incyte's Povorcitinib Shows Promise but Faces Competitive Challenges: Hold Rating Maintained

Jessica Fye

J.P. Morgan

$67→$73

Hold

-16.26%

Downside

Reiterated

08/22/25

Incyte price target raised to $73 from $67 at JPMorganIncyte price target raised to $73 from $67 at JPMorgan

Derek Archila

Wells Fargo

$67→$89

Buy

2.10%

Upside

Upgraded

08/06/25

Analysts Conflicted on These Healthcare Names: Incyte (NASDAQ: INCY) and Y-Mabs Therapeutics (NASDAQ: YMAB)

Evan Seigerman

BMO Capital

$60

Sell

-31.17%

Downside

Reiterated

08/04/25

Incyte (INCY) Receives a Sell from BMO Capital

Mara Goldstein

Mizuho Securities

$70→$74

Hold

-15.11%

Downside

Reiterated

08/04/25

David Lebowitz

Citi

$88→$103

Buy

18.16%

Upside

Reiterated

07/30/25

Incyte price target raised to $103 from $88 at CitiIncyte price target raised to $103 from $88 at Citi

Andrew Berens

Leerink Partners

$96→$103

Buy

18.16%

Upside

Reiterated

07/30/25

Incyte's Strong Financial Performance and Strategic Initiatives Under New Leadership Drive Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Incyte

1 Month

xxx

Success Rate

10/15 ratings generated profit

Average Return

-0.68%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of -0.68% per trade.

3 Months

xxx

Success Rate

9/15 ratings generated profit

Average Return

+4.07%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +4.07% per trade.

1 Year

David LebowitzCiti

Success Rate

15/15 ratings generated profit

Average Return

+22.45%

reiterated a buy rating 2 months ago

Copying David Lebowitz's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +22.45% per trade.

2 Years

xxx

Success Rate

15/15 ratings generated profit

Average Return

+34.39%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +34.39% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

INCY Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, INCY has received 23 Buy Ratings, 16 Hold Ratings, and 3 Sell Ratings. INCY average Analyst price target in the past 3 months is 85.71.

Each month's total comprises the sum of three months' worth of ratings.

INCY Financial Forecast

INCY Earnings Forecast

Next quarter’s earnings estimate for INCY is $1.61 with a range of $1.09 to $1.85. The previous quarter’s EPS was $1.57. INCY beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year INCY has Preformed in-line its overall industry.

INCY Sales Forecast

Next quarter’s sales forecast for INCY is $1.25B with a range of $1.20B to $1.31B. The previous quarter’s sales results were $1.22B. INCY beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year INCY has Preformed in-line its overall industry.

INCY Stock Forecast FAQ

What is INCY’s average 12-month price target, according to analysts?

Based on analyst ratings, Incyte Corp’s 12-month average price target is 85.71.

What is INCY’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for INCY, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is INCY a Buy, Sell or Hold?

Incyte Corp has a consensus rating of Moderate Buy which is based on 8 buy ratings, 10 hold ratings and 1 sell ratings.

What is Incyte Corp’s price target?

The average price target for Incyte Corp is 85.71. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $115.00 ,the lowest forecast is $60.00. The average price target represents -1.67% Decrease from the current price of $87.17.

What do analysts say about Incyte Corp?

Incyte Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of INCY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Incyte (INCY) Stock Forecast & Price Target

INCY Analyst Ratings

INCY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Incyte

INCY Analyst Recommendation Trends

INCY Financial Forecast

INCY Earnings Forecast

INCY Sales Forecast

INCY Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts